Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 6 · 85.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Inhaled tobramycin (TNS) (28 days) vs TNS (56 days)

Eradication of P aeruginosa from the respiratory tract: time to next isolation of P aeruginosa from BAL, sputum or oropharyngeal cultures · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Inhaled tobramycin (TNS) (28 days) vs TNS (56 days)

FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 88 participants
Very low

Inhaled tobramycin (TNS) (28 days) vs TNS (56 days)

Growth and nutritional status · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 88 participants
Very low

Inhaled tobramycin (TNS) (28 days) vs TNS (56 days)

Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

It is very uncertain whether inhaled tobramycin (TNS) (28 days) changes frequency of infective pulmonary exacerbations: number of… compared with TNS (56 days) (very low certainty).

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
OR 0.19 [0.01, 4]
1 study · 77 participants
Very low

Inhaled tobramycin (TNS) (28 days) vs TNS (56 days)

Isolation of other micro‐organisms from the respiratory tract: number of positive cultures per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 88 participants
Very low

Inhaled tobramycin (TNS) (28 days) vs TNS (56 days)

Adverse effects of antibiotics · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 77 participants
Very low

Inhaled tobramycin (TNS) (28 days) vs TNS (56 days)

FEV1 % predicted · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 88 participants
Very low